Clinical Trial Update: A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) [Phase 3]

View source ↗

Summary

A Phase 3b study evaluating vernakalant injection for recent-onset symptomatic atrial fibrillation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Vernakalant Injection (vernakalant)

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Fibrillation | Phase 3 | Status: TERMINATED